Evaluation of the effect of herbal therapeutic supplements (Marsh - Mallow, Sweet violet, Malva sylvestris, Damask rose, Liquorice root) against corona disease

ABSTRACT

ConditionCOVID-19.
COVID-19, virus identified;U07.1

InterventionIntervention 1 Intervention group The drug (including tea, honey and royal jelly for 5 days) is delivered to the hospital along with the list of codes of patients in the intervention group (to be presented to patients in the intervention group).The composition inside each CRSM-X7 tea bag includes 10 grams of marshmallow, 5 grams of Sweet violet, 5 grams of Wild mallow, 5 grams of Damask rose, 10 grams of Liquorice root. After identification and registration, they will be placed in special bags for use. Each bag of CRSM-X7 herbal tea is infused in a volume of 300 ml of boiling water for one day use. After the temperature of the drink is reduced (it reached the temperature of 40 ° C), 5 cc of lavender honey is added, dissolved in it and drunk. So that, three glasses (each glass is equivalent to 100 ml) will be drunk per day (half an hour before breakfast, one hour before lunch, one hour before bedtime) up to five days by the intervention group. The seventh element of this supplement is Royal Jelly, which is prepared in the proportion of 50 grams of Royal Jelly in one kilo gram of lavender honey and should be used by the people under study 4 meals a day, ie morning, noon, evening, night for 5 days (each Promise of 2.5 cc). Intervention 2 Control group Control group 92 people are in the control group, which includes other patients and hospitalized in the same treatment center who receive a standard treatment regimen similar to the intervention group.

Primary outcome:Hospitalization time. Timepoint Before starting the study and after 5 days of using herbal supplements. Method of measurement A researcher-made questionnaire whose validity and reliability have been assessed.

CriteriaInclusion criteria Diagnosis of COVID-19
Age 18-65
Having informed and written consent to participate in the study

Exclusion criteria Disagreement of the physician directly responsible for the patient
Pregnancy and breastfeeding
Allergies to the drug elements
Symptoms of gastrointestinal, liver or kidney disease
Incidence of drug interactions
Patient dissatisfaction to continue the project for any reason
Inability of the patient to receive oral medication
Hypertension
Having heart failure
Do not take anticoagulants (aspirin, Plavix, warfarin)